It was too good to be true: Addiction-free opioids appear to still be a fantasy.
In the wake of a recent lab test, the Food and Drug Administration appears less likely to approve use of a painkiller that its manufacturer, New York City-based Pfizer Inc., is touting as being less vulnerable to abuse. The agency conducted a review of the drug, and found that oxycodone can still be extracted from the pills with solvents.
The review found that a number of easily-accessible solvents could allow for easy extraction of the powerful drug, contrary to Pfizer's own claim that only one specific solvent would do the trick.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
